三种抗菌药物治疗耐甲氧西林金黄色葡萄球菌感染的经济学分析  

Assessment of Three Types of Antimicrobial Agents for Methicillin-resistant Staphylococcus Aureus Infection

作　　者：杨志忠[1] 杨洋[2] 陈赫军[3] 平泽[3] 方妍[3] 李洁[3] 

机构地区：[1]哈励逊国际和平医院制剂室,河北衡水053000 [2]哈励逊国际和平医院营养科,河北衡水053000 [3]哈励逊国际和平医院药学部,河北衡水053000

出　　处：《解放军药学学报》2016年第2期174-176,共3页Pharmaceutical Journal of Chinese People's Liberation Army

摘　　要：目的比较3种治疗耐甲氧西林金黄色葡萄球菌(MRSA)感染药物的成本-效果,为临床合理用药提供参考。方法回顾性研究2011年3月—2014年5月的MRSA肺部感染患者150例,按不同的抗菌药物治疗方案分成夫西地酸钠组、万古霉素组和替考拉宁组,各50例,运用药物经济学中的成本-效果分析等方法对其进行分析。结果夫西地酸钠组、万古霉素组和替考拉宁组的临床有效率分别为68.0%、70.0%、80.0%,不良反应发生率分别为10.0%、18.0%、6.0%,成本分别为7437.4元、6805.7元、6966.7元,成本-效果比分别为109.37、97.22、87.08。结论替考拉宁治疗MRSA感染的经济性优于夫西地酸钠和万古霉素。Objective To investigate the cost and effectiveness of three kinds of antimicrobial agents for methicillin-resistant Staphylococcus aureus（ MRSA） infection in order to provide reference for clinical rational use of drugs. Methods A retrospective study was made of 150 patients with MRSA infection from March of 2011 to May of2014. These patients were divided into three groups according to antibacterial therapies： sodium fusidate group,vancomycin group and teicoplanin group,with 50 patients in each group. Cost-effectiveness analysis and other methods were applied to these cases. Results The clinical efficiency of the three groups was 68. 0%,70. 0%,80. 0% respectively,the rate of ADRs was 10. 0%,18. 0%,6. 0% respectively,the cost was 7437. 4 yuan,6805. 7 yuan and6966. 7 yuan respectively,and the cost-effectiveness ratio was 109. 37,97. 22 and 87. 08 respectively. Conclusion Teicoplanin is a better treatment option for MRSA infection than sodium fusidate and vancomycin.

关 键 词：夫西地酸钠 万古霉素 替考拉宁 耐甲氧西林金黄色葡萄球菌 成本-效果分析 

分 类 号：R95[医药卫生—药学]